Moreover, MLL frequently hosts international research cooperation directly: For instance through exchange programs, our test procedures and data repositories, but also by allowing guest researchers to shadow the work of our facility and by sitting on national and international work groups.

We also support research institutions around the world to produce new insight in the field of leukemia diagnostics and emergence, as well as in the rollout of new procedures and applications for routine diagnostics in the facilities themselves.


Our research findings are published in international, peer-reviewed journals and feature in conference talks and lectures, as well as in poster presentations and at scientific events.

Alpermann T, Kern W, Schnittger S, Schmid C, Kreuzer KA, Serve H, Pielken HJ, Schmitz N, Wendtner CM, Haferlach C, Haferlach T. Evaluation of the proposed reporting system of the European LeukemiaNet and recommendations for prognosis of acute myeloid leukemia. Leuk Res. 2013;37(2):197-200.

Bacher U, Haferlach C, Alpermann T, Schnittger S, Kern W, Haferlach T. Patients with therapy-related myelodysplastic syndromes and acute myeloid leukemia share genetic features but can be separated by blast counts and cytogenetic risk profiles into prognostically relevant subgroups. Leuk Lymphoma. 2013;54(3):639-42.

Bacher U, Haferlach T, Alpermann T, Kern W, Schnittger S, Haferlach C. Molecular mutations are prognostically relevant in AML with intermediate risk cytogenetics and aberrant karyotype. Leukemia. 2013;27(2):496-500.

Bacher U, Kern W, Haferlach C, Alpermann T, Haferlach T, Schnittger S. Cyclin D1 (CCND1) mRNA expression as assessed by real-time PCR contributes to diagnosis and follow-up control in patients with mantle cell lymphoma. Exp Hematol. 2013;41(12):1028-1037.

Bödör C, Grossmann V, Popov N, Okosun J, O'Riain C, Tan K, Marzec J, Araf S, Wang J, Lee AM, Clear A, Montoto S, Matthews J, Iqbal S, Rajnai H, Rosenwald A, Ott G, Campo E, Rimsza LM, Smeland EB, Chan WC, Braziel RM, Staudt LM, Wright G, Lister TA, Elemento O, Hills R, Gribben J, Chelala C, Matolcsy A, Kohlmann A, Haferlach T, Gascoyne RD, Fitzgibbon J. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood. 2013;122(18):3165-3168.

Broséus J, Alpermann T, Wulfert M, Brichs LF, Jeromin S, Lippert E, Rozman M, Lifermann F, Grossmann V, Haferlach T, Germing U, Luño E, Girodon F, Schnittger S. Age, JAK2V617F and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia. 2013;27(9):1826-1831.

Chase A, Bryant C, Score J, Haferlach C, Grossmann V, Schwaab J, Hofmann WK, Reiter A, Cross NC. Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements. Haematologica. 2013;98(3):404-408.

Christopeit M, Heiland A, Binder M, Zabelina T, Ayuk F, Horn C, Haferlach T, Bokemeyer C, Kröger N, Bacher U. Impact of physiological BM CD10+CD19+ B-cell precursors (haematogones) in the post-transplant period in patients with AML. Bone Marrow Transplant. 2013;48(9):1257-1259.

Christopeit M, Kuss O, Finke J, Bacher U, Beelen DW, Bornhäuser M, Schwerdtfeger R, Bethge WA, Basara N, Gramatzki M, Tischer J, Kolb HJ, Uharek L, Meyer RG, Bunjes D, Scheid C, Martin H, Niederwieser D, Kröger N, Bertz H, Schrezenmeier H, Schmid C. Second Allograft for Hematologic Relapse of Acute Leukemia After First Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors: The Role of Donor Change. J Clin Onol. 2013;31(26):3259-3271.

Christopeit M, Ocheni S, Haferlach T, Miersch K, Zabelina T, Klyuchnikov E, Binder M, Ayuk F, Schafhausen P, Zander AR, Bokemeyer C, Kröger N, Bacher U. Evaluation of BM cytomorphology after allo-SCT in patients with MDS. Bone Marrow Transplant. 2013;48(3):465-466.

1 / 5